Assessing Novo Nordisk After Recent Volatility and Debate Over Obesity Drug Pricing [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
The stock has bounced sharply in the short term, up 10.0% over the last week and 16.9% over the last month, but that is against a much tougher backdrop with returns of -39.9% year to date and -38.6% over the past year, even though the five year return is still a solid 59.1%. Recent headlines have kept Novo Nordisk at the center of the market conversation, from ongoing global demand for its diabetes and obesity treatments to regulatory and policy debates around drug pricing and access in key markets. Investors are weighing how these developments could shape long term revenue durability, competitive positioning, and ultimately what a fair price for the stock looks like today. On our checks, Novo Nordisk scores a strong 5 out of 6 for undervaluation, which suggests there is more to the story than the headline share price moves. Next, we will walk through different valuation approaches to see how they line up, before finishing with a more powerful way to think about Novo Nordisk's va
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk (NVO) Rises Higher Than Market: Key Facts [Yahoo! Finance]Yahoo! Finance
- Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely [Seeking Alpha]Seeking Alpha
- FDA approves Novo Nordisk's weight-loss pill [FOX Business Network]FOX Business Network
- Novo Nordisk: The Real Comeback Starts Now With The Wegovy Pill [Seeking Alpha]Seeking Alpha
- Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 12/23/25 - Form 6-K
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- NVO's page on the SEC website